- Home
- RLAY vs SRAD Comparison
RLAY vs SRAD Comparison
Compare RLAY & SRAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLAY | SRAD |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.3B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RLAY | SRAD |
|---|---|---|
| Price | $18.37 | $14.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 16 |
| Target Price | $19.50 | ★ $24.31 |
| AVG Volume (30 Days) | ★ 4.1M | 2.5M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,355,000.00 | N/A |
| Revenue This Year | N/A | $24.03 |
| Revenue Next Year | $324.03 | $14.81 |
| P/E Ratio | ★ N/A | $49.48 |
| Revenue Growth | ★ 53.44 | N/A |
| 52 Week Low | $3.03 | $11.66 |
| 52 Week High | $19.93 | $32.22 |
Technical Indicators
Market Signals| Indicator | RLAY | SRAD |
|---|---|---|
| Relative Strength Index (RSI) | 64.92 | 52.52 |
| Support Level | $6.67 | $14.54 |
| Resistance Level | N/A | $17.43 |
| Average True Range (ATR) | 1.03 | 0.67 |
| MACD | 0.21 | -0.06 |
| Stochastic Oscillator | 77.66 | 25.35 |
Price Performance
Historical ComparisonAbout RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
About SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.